Compare · AVTR vs CTKB
AVTR vs CTKB
Side-by-side comparison of Avantor Inc. (AVTR) and Cytek Biosciences Inc. (CTKB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and CTKB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $10.62B, about 15.1x CTKB ($701.3M).
- Over the past year, AVTR is up 10.6% and CTKB is up 34.6% - CTKB leads by 24.0 points.
- AVTR has been more active in the news (6 items in the past 4 weeks vs 2 for CTKB).
- AVTR has more recent analyst coverage (25 ratings vs 13 for CTKB).
- Company
- Avantor Inc.
- Cytek Biosciences Inc.
- Price
- $16.09+2.32%
- $5.41+0.28%
- Market cap
- $10.62B
- $701.3M
- 1M return
- +3.07%
- +9.74%
- 1Y return
- +10.62%
- +34.58%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 13
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Latest AVTR
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
- EVP and CFO Garner Todd W was granted 49,688 shares (SEC Form 4)
- SEC Form 3 filed by new insider Garner Todd W
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor appoints new Chief Financial Officer
- UBS initiated coverage on Avantor with a new price target
- Amendment: Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
Latest CTKB
- SEC Form 8-K filed by Cytek Biosciences Inc.
- Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
- Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
- Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
- PRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax
- Director Muir Glenn P converted options into 3,086 shares (SEC Form 4)